Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

337 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Allogeneic myeloablative transplantation for patients aged 50 years and over.
Yanada M, Emi N, Naoe T, Sakamaki H, Iseki T, Hirabayashi N, Karasuno T, Chiba S, Atsuta Y, Hamajima N, Takahashi S, Kato S. Yanada M, et al. Among authors: hirabayashi n. Bone Marrow Transplant. 2004 Jul;34(1):29-35. doi: 10.1038/sj.bmt.1704518. Bone Marrow Transplant. 2004. PMID: 15156161
Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan.
Yanada M, Emi N, Naoe T, Sakamaki H, Takahashi S, Hirabayashi N, Hiraoka A, Kanda Y, Tanosaki R, Okamoto S, Iwato K, Atsuta Y, Hamajima N, Tanimoto M, Kato S. Yanada M, et al. Among authors: hirabayashi n. Bone Marrow Transplant. 2004 Aug;34(4):331-7. doi: 10.1038/sj.bmt.1704596. Bone Marrow Transplant. 2004. PMID: 15220958
Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party.
Kataoka I, Kami M, Takahashi S, Kodera Y, Miyawaki S, Hirabayashi N, Okamoto S, Matsumoto N, Miyazaki Y, Morishita Y, Asai O, Maruta A, Yoshida T, Imamura M, Hamajima N, Matsuo K, Harada M, Mineishi S; Japan Society for Hematopoietic Cell Transplantation Working Party. Kataoka I, et al. Among authors: hirabayashi n. Bone Marrow Transplant. 2004 Oct;34(8):711-9. doi: 10.1038/sj.bmt.1704659. Bone Marrow Transplant. 2004. PMID: 15361916
Significance of additional high-dose cytarabine in combination with cyclophosphamide plus total body irradiation regimen for allogeneic stem cell transplantation.
Inamoto Y, Nishida T, Suzuki R, Miyamura K, Sao H, Iida H, Naoe T, Maruyama F, Hirabayashi N, Hamaguchi M, Iseki T, Kami M, Yano K, Takeyama H, Morishita Y, Morishima Y, Kodera Y. Inamoto Y, et al. Among authors: hirabayashi n. Bone Marrow Transplant. 2007 Jan;39(1):25-30. doi: 10.1038/sj.bmt.1705543. Epub 2006 Nov 20. Bone Marrow Transplant. 2007. PMID: 17115063
Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy.
Inamoto Y, Ito M, Suzuki R, Nishida T, Iida H, Kohno A, Sawa M, Murata M, Nishiwaki S, Oba T, Yanada M, Naoe T, Ichihashi R, Fujino M, Yamaguchi T, Morishita Y, Hirabayashi N, Kodera Y, Miyamura K; Nagoya Blood and Marrow Transplantation Group. Inamoto Y, et al. Among authors: hirabayashi n. Bone Marrow Transplant. 2009 Jul;44(1):43-9. doi: 10.1038/bmt.2008.419. Epub 2009 Jan 12. Bone Marrow Transplant. 2009. PMID: 19139727
Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000).
Kanda Y, Chiba S, Hirai H, Sakamaki H, Iseki T, Kodera Y, Karasuno T, Okamoto S, Hirabayashi N, Iwato K, Maruta A, Fujimori Y, Furukawa T, Mineishi S, Matsuo K, Hamajima N, Imamura M. Kanda Y, et al. Among authors: hirabayashi n. Blood. 2003 Aug 15;102(4):1541-7. doi: 10.1182/blood-2003-02-0430. Epub 2003 Apr 24. Blood. 2003. PMID: 12714500 Free article.
Impact of cytogenetics on outcome of stem cell transplantation for acute myeloid leukemia in first remission: a large-scale retrospective analysis of data from the Japan Society for Hematopoietic Cell Transplantation.
Ogawa H, Ikegame K, Kawakami M, Takahashi S, Sakamaki H, Karasuno T, Sao H, Kodera Y, Hirabayashi N, Okamoto S, Harada M, Iwato K, Maruta A, Tanimoto M, Kawa K; Japan Society for Hematopoietic Cell Transplantation. Ogawa H, et al. Among authors: hirabayashi n. Int J Hematol. 2004 Jun;79(5):495-500. doi: 10.1532/ijh97.03166. Int J Hematol. 2004. PMID: 15239403
Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia.
Kodera Y, Morishima Y, Kato S, Akiyama Y, Sao H, Matsuyama T, Kawa K, Sakamaki H, Nakagawa S, Hirabayashi N, Dohi H, Okamoto S, Hiraoka A, Gondo H, Tsuchida M, O H, Harada M, Asano S, Juji T, Sasazuki T, Takaku F. Kodera Y, et al. Among authors: hirabayashi n. Bone Marrow Transplant. 1999 Nov;24(9):995-1003. doi: 10.1038/sj.bmt.1702027. Bone Marrow Transplant. 1999. PMID: 10556959
337 results